Evidence map›Paper›PMID 36435706›Full record

ArticleVaccine2023

SARS-CoV-2 viral shedding in vaccinated and unvaccinated persons: A case series.

David W McCormick, Liesl M Hagan, Phillip P Salvatore, Reed Magleby, Christine Lee, Sadia Sleweon, Lavinia Nicolae, Tom Dixon, Robert Banta, Isaac Ogle and 16 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Vaccine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact, top 83% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

26 authors at 3 institutions in 1 country.

David W McCormickCOVID-19 Pandemic Response Team, Centers for Disease Control and Prevention, Atlanta, GA, United States; Epidemic Intelligence Service, Centers for Disease Control and Prevention, Atlanta, GA, United States; United States Public Health Service, Rockville, MD, United States. Electronic address: yup1@cdc.gov.
Liesl M HaganCOVID-19 Pandemic Response Team, Centers for Disease Control and Prevention, Atlanta, GA, United States.
Phillip P SalvatoreCOVID-19 Pandemic Response Team, Centers for Disease Control and Prevention, Atlanta, GA, United States; United States Public Health Service, Rockville, MD, United States. Electronic address: pgx5@cdc.gov.
Reed MaglebyCOVID-19 Pandemic Response Team, Centers for Disease Control and Prevention, Atlanta, GA, United States; Epidemic Intelligence Service, Centers for Disease Control and Prevention, Atlanta, GA, United States.
Christine LeeCOVID-19 Pandemic Response Team, Centers for Disease Control and Prevention, Atlanta, GA, United States; Laboratory Leadership Service, Centers for Disease Control and Prevention, Atlanta, GA, United States.
Sadia SleweonCOVID-19 Pandemic Response Team, Centers for Disease Control and Prevention, Atlanta, GA, United States.
Lavinia NicolaeCOVID-19 Pandemic Response Team, Centers for Disease Control and Prevention, Atlanta, GA, United States.
Tom DixonBureau of Prisons, U.S. Department of Justice, Washington, DC, United States.
Robert BantaBureau of Prisons, U.S. Department of Justice, Washington, DC, United States.
Isaac OgleUnited States Public Health Service, Rockville, MD, United States; Bureau of Prisons, U.S. Department of Justice, Washington, DC, United States.
Cristen YoungBureau of Prisons, U.S. Department of Justice, Washington, DC, United States.
Charles DusseauBureau of Prisons, U.S. Department of Justice, Washington, DC, United States.
Charles OgdenUnited States Public Health Service, Rockville, MD, United States; Bureau of Prisons, U.S. Department of Justice, Washington, DC, United States.
Hannah BrowneCOVID-19 Pandemic Response Team, Centers for Disease Control and Prevention, Atlanta, GA, United States.
John Michael MetzCOVID-19 Pandemic Response Team, Centers for Disease Control and Prevention, Atlanta, GA, United States.
Min-Hsin ChenCOVID-19 Pandemic Response Team, Centers for Disease Control and Prevention, Atlanta, GA, United States.
Maria I SolanoCOVID-19 Pandemic Response Team, Centers for Disease Control and Prevention, Atlanta, GA, United States.
Shannon RogersCOVID-19 Pandemic Response Team, Centers for Disease Control and Prevention, Atlanta, GA, United States.
Alex BurginCOVID-19 Pandemic Response Team, Centers for Disease Control and Prevention, Atlanta, GA, United States.
Mili ShethCOVID-19 Pandemic Response Team, Centers for Disease Control and Prevention, Atlanta, GA, United States.
Bettina BankampCOVID-19 Pandemic Response Team, Centers for Disease Control and Prevention, Atlanta, GA, United States.
Azaibi TaminCOVID-19 Pandemic Response Team, Centers for Disease Control and Prevention, Atlanta, GA, United States.
Jennifer L HarcourtCOVID-19 Pandemic Response Team, Centers for Disease Control and Prevention, Atlanta, GA, United States.
Jacqueline E TateCOVID-19 Pandemic Response Team, Centers for Disease Control and Prevention, Atlanta, GA, United States; United States Public Health Service, Rockville, MD, United States.
Hannah L KirkingCOVID-19 Pandemic Response Team, Centers for Disease Control and Prevention, Atlanta, GA, United States; United States Public Health Service, Rockville, MD, United States.
COVID-19 Surge Diagnostics Laboratory Teams
Centers for Disease Control and Prevention · USUnited States Department of Justice · USUnited States Public Health Service · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The preclinical time course of SARS-CoV-2 shedding is not well-described. Understanding this time course will help to inform risk of SARS-CoV-2 transmission. During an outbreak in a congregate setting, we collected paired mid-turbinate nasal swabs for antigen testing and reverse-transcription polymerase chain reaction (RT-PCR) every other day from all consenting infected and exposed persons. Among 12 persons tested prospectively before and during SARS-CoV-2 infection, ten of 12 participants (83%) had completed a primary COVID-19 vaccination series prior to the outbreak. We recovered SARS-CoV-2 in viral culture from 9/12 (75%) of participants. All three persons from whom we did not recover SARS-CoV-2 in viral culture had completed their primary vaccination series. We recovered SARS-CoV-2 from viral culture in 6/9 vaccinated persons and before symptom onset in 3/6 symptomatic persons. These findings underscore the need for both non-pharmaceutical interventions and vaccination to mitigate transmission.

Indexed as

COVID-19SARS-CoV-2COVID-19 TestingCOVID-19 VaccinesHumansVirus SheddingCOVID-19 VaccinesCOVID-19 vaccinesPrisonsSARS-CoV-2Virus shedding

Identifiers

PMID36435706
PMCPMC9671797
OpenAlexW4309470049

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.